Athira Pharma (Athira Pharma) Shares Outstanding (Diluted Average) : 38.10 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Athira Pharma Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Athira Pharma's average diluted shares outstanding for the quarter that ended in Dec. 2023 was 38.10 Mil.

Athira Pharma Shares Outstanding (Diluted Average) Historical Data

The historical data trend for Athira Pharma's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athira Pharma Shares Outstanding (Diluted Average) Chart

Athira Pharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Shares Outstanding (Diluted Average)

Get a 7-Day Free Trial

8.60

11.97

36.92

37.73

38.02

Athira Pharma Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Shares Outstanding (Diluted Average)	Get a 7-Day Free Trial															37.85	37.92	38.00	38.06	38.10

Athira Pharma Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

Athira Pharma (NAS:ATHA) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

Athira Pharma Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of Athira Pharma's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.

Athira Pharma (Athira Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athira Pharma Inc (NAS:ATHA) » Definitions » Shares Outstanding (Diluted Average)

Comparable Companies

Traded in Other Exchanges

N/A

Address

18706 North Creek Parkway, Suite 104, Bothell, WA, USA, 98011

Website

https://www.athira.com

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

Executives

Mark James Litton	officer: Chief Operating Officer	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Mark Worthington	officer: General Counsel	C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011
Rachel Lenington	officer: Chief Technology Officer	C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Andrew Gengos	officer: See Below	21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Grant Pickering	director	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
James A Johnson	director	C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102
Kevin Church	officer: Vice President of Discovery	4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Glenna Mileson	officer: Chief Financial Officer	4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Kelly A Romano	director	C/O DORMAN PRODUCTS, INC., 3400 EAST WALNUT STREET, COLMAR PA 18915
Hans Moebius	officer: Chief Medical Officer	4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Michael A. Panzara	director	733 CONCORD AVENUE, CAMBRIDGE MA 02138
Barbara Kosacz	director	3175 HANOVER STREET, PALO ALTO CA 94304
Joseph Edelman	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014